Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin

Antiviral Therapy

Volumn 12, Issue 4, 2007, Pages 469-476

  Soriano, Vincent ^a   Miralles, Celia ^b   Berdún, Miguel Angel ^c   Losada, Elena ^d   Aguirrebengoa, Koldo ^e   Ocampo, Antonio ^b   Arazo, Piedad ^f   Cervantes, Manuel ^g   De Los Santos, Ignacio ^h   San Joaquín, Isabel ⁱ   Echeverria, Santiago ^j   Galindo, María J ^k   Asensi, Victor ^l   Barreiro, Pablo ^a   Sola, Julio ^m   Hernandez Burruezo, Juan J ⁿ   Guardiola, Josep ^o   Blanco, Francisco ^a   Martin Carbonero, Luz ^a   García Samaniego, Javier ^a   Nuñez, Marina ^a   more..

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL XERAL CÍES   (Spain)

^c HOSPITAL SAN JORGE   (Spain)

^d Instituto de Salud Carlos III   (Spain)

^e HOSPITAL DE CRUCES   (Spain)

^f HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^g HOSPITAL DE SABADELL   (Spain)

^h HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^j HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^k HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^l HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^m Universidad Pública de Navarra   (Spain)

ⁿ Hospital General   (Spain)

^o HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; RIBAVIRIN; ZIDOVUDINE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BACTEREMIA; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL DISEASE; GENOTYPE; HAIR LOSS; HEADACHE; HEMATOLOGIC DISEASE; HEPATITIS C; HEPATITIS C VIRUS; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHYROIDISM; INSOMNIA; LACTIC ACIDOSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PANCREATITIS; PNEUMONIA; PRIORITY JOURNAL; RETINOPATHY; SIDE EFFECT; SKIN MANIFESTATION; SUICIDE ATTEMPT; THROMBOCYTOPATHY; THROMBOCYTOPENIA; TREATMENT WITHDRAWAL; WEIGHT REDUCTION;

ADULT; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON ALFA-2A; MALE; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 34447287588     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Rockstroh J, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192:992-1002.
2. Sulkowski M, Mast E, Seeff L, Thomas D. HCV infection as an opportunistic disease in persons infected with HIV. Clin Infect Dis 2000; 30(Suppl 1):77-84.
3. Martin-Carbonero L, Soriano V, Valencia E, García-Samaniego I, López M, González-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001; 17:1467-1471.
4. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with HIV infection. Clin Infect Dis 2001; 32:492-497.
5. Torriani F, Rodriguez-Torres M, Rockstroh J, et al. for the APRICOT trial. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450.
6. Carrat F, Bani-Sadr F, Pol S, et al. for the RIBAVIC trial. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients. JAMA 2004; 292:2839-2848.
7. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18:F27-36.
8. Chung R, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-459.
9. Manns M, McHutchison J, Gordon S, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358:958-965.
10. Fried M, Shiffman M, Reddy K, et al. Peginterferon alfa-2a plus ribavirin for chronic HCV infection. N Engl J Med 2002; 347:975-982.
11. Hadziyannis S, Sette H, Morgan T, et al. Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
12. Torriani F, Ribeiro R, Gilbert T, et al. HCV and HIV dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis 2003; 188:1498-507.
13. Herrmann E, Lee J, Marison G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003; 37:1351-1358.
14. Dixit N, Layden-Almer J, Layden T, Perelson A. Modeling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004; 432:922-924.
15. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357:280-281.
16. Mauss S, Valenti W, DePamphilis J, et al. for the APRICOT Team. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon therapy. AIDS 2004; 18:F21-25.
17. Rendon A, Nuñez M, Romero M, Soriano V. Early monitoring of ribavirin plasma concentrations may predict anemia and early virological response in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2005; 39:401-405.
18. Nuñez M, Miralles C, Berdun MA, et al. for the PRESCO Team. Role of extended therapy and/or optimal doses of ribavirin in the treatment of chronic hepatitis C in HIV-infected patients with peginterferon alfa-2a plus ribavirin: the PRESCO trial. AIDS Res Hum Retroviruses: in press.
19. Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV co-infection. Updated recommendations from the HIV-HCV International Panel. AIDS 2004; 18:1-12.
20. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42:615-624.
21. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C. Hepatology 2002; 36:3-20.
22. Soriano V, Perez-Olmeda M, Rios P, Nunez M, Garcia-Samaniego J, Gonzalez-Lahoz J. Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients. AIDS Res Hum Retroviruses 2004; 20:351-353.
23. Voigt E, Schulz C, Klausen G, Rockstroh J. Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV coinfected patients. J Infect 2005; 51:245-249.
24. Bani-Sadr F, Carrat F, Pol S, et al. for the RIBAVIC Team. Risk factors for symptomatic mitochondrial toxicity in HIV/HCV-coinfected patients during interferon plus ribavirin-based therapy. J Acquir Immune Defic Syndr 2005; 40:47-52.
25. Alvarez D, Dieterich D, Brau N, Moorehead L, Ball L, Sulkowski M. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat 2006; 13:683-689.
26. Gallant J, De Jesus E, Arribas J, et al. for the ACTG 934. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260.
27. Berg T, von Wagner M, Nasser S, Zeuzem S. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa 2a plus ribavirin. Gastroenterology 2006; 130:1086-1097.
28. Uriel A, Moorehead L, Carriero D, Sulkowski M, Dieterich D, and the Hepatitis Resource Network Clinical Trials Group. A multicenter, randomized trial of 48 vs 72 weeks of peg interferon-α2b + ribavirin in HIV/HCV co-infected subjects: longer therapy does not correlate with improved sustained virological response. 13th Conference on Retroviruses & Opportunistic Infections. 5-8 February 2006, Denver, CO, USA. Abstract 854.